User profiles for Nuria Labiod
 | Nuria Labiod BecerroInvestigadora, Centro Nacional de Microbiología Verified email at isciii.es Cited by 323 |
[HTML][HTML] MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression
…, I Ríos, C Herrero, F Lasala, N Labiod… - JCI insight, 2023 - ncbi.nlm.nih.gov
Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19,
are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (…
are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (…
[HTML][HTML] DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
M Thépaut, J Luczkowiak, C Vivès, N Labiod… - PLoS …, 2021 - journals.plos.org
The efficient spread of SARS-CoV-2 resulted in a unique pandemic in modern history.
Despite early identification of ACE2 as the receptor for viral spike protein, much remains to be …
Despite early identification of ACE2 as the receptor for viral spike protein, much remains to be …
[HTML][HTML] Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
…, L Sánchez-Paz, J Luczkowiak, N Labiod… - Frontiers in …, 2022 - frontiersin.org
Background SARS-CoV-2 vaccination has proven the most effective measure to control the
COVID-19 pandemic. Booster doses are being administered with limited knowledge on their …
COVID-19 pandemic. Booster doses are being administered with limited knowledge on their …
[HTML][HTML] Survey of Crimean-Congo hemorrhagic fever enzootic focus, Spain, 2011–2015
During 2011–2015, we conducted a Crimean-Congo hemorrhagic fever virus (CCHFV)
survey in captured ticks that were feeding mainly on wild and domestic ungulates in Spain, …
survey in captured ticks that were feeding mainly on wild and domestic ungulates in Spain, …
[HTML][HTML] Optimized vaccine candidate MVA-S (3P) fully protects against SARS-CoV-2 infection in hamsters
…, L Coelmont, B Weynand, N Labiod… - Frontiers in …, 2023 - frontiersin.org
The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19)
that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-…
that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-…
Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19–convalescent individuals
J Luczkowiak, N Labiod, G Rivas, M Rolo… - The Journal of …, 2022 - academic.oup.com
We have investigated the evolution of the neutralizing response against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants at 8 months after Pfizer-BNT162b2 …
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants at 8 months after Pfizer-BNT162b2 …
Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses
…, MA Cuesta-Geijo, I García-Dorival, P Bueno, N Labiod… - Antiviral research, 2021 - Elsevier
Despite the efforts to develop new treatments against Ebola virus (EBOV) there is currently
no antiviral drug licensed to treat patients with Ebola virus disease (EVD). Therefore, there is …
no antiviral drug licensed to treat patients with Ebola virus disease (EVD). Therefore, there is …
Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
J Luczkowiak, G Rivas, N Labiod… - Journal of Medical …, 2023 - Wiley Online Library
We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19
naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a …
naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a …
Prime-boost vaccination with BNT162b2 induces high neutralizing activity against SARS-CoV-2 variants in naive and COVID-19-convalescent individuals
J Luczkowiak, N Labiod, G Rivas, M Rolo… - Open Forum …, 2021 - academic.oup.com
Background The objective of this study was to investigate the neutralizing response against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) …
Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
…, S Flores, J Luczkowiak, N Labiod… - Advanced …, 2023 - Wiley Online Library
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing
immediate protection against SARS‐CoV‐2. However, dual strategies combining virus …
immediate protection against SARS‐CoV‐2. However, dual strategies combining virus …
